Inhibition of FOXM1 by thiostrepton sensitizes medulloblastoma to the effects of chemotherapy

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1739-1744

  Lin, Jiaping ^a   Zheng, Yipeng ^a   Chen, Kun ^a   Huang, Zhengsong ^a   Wu, Xinjian ^a   Zhang, Nu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chemotherapy; FOXM1; Medulloblastoma; Thiostreptin

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; CISPLATIN; SMALL INTERFERING RNA; THIOSTREPTON; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL CYCLE ARREST; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; MEDULLOBLASTOMA; METASTASIS INHIBITION; METASTASIS POTENTIAL; PRIORITY JOURNAL; RNA INTERFERENCE; TRANSCRIPTION TERMINATION; TUMOR INVASION;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; FORKHEAD TRANSCRIPTION FACTORS; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; HUMANS; MEDULLOBLASTOMA; NEOPLASM INVASIVENESS; RNA INTERFERENCE; RNA, SMALL INTERFERING; THIOSTREPTON;

EID: 84882659453     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2654     Document Type: Article

References (30)

1. von Hoff K, Hinkes B, Gerber NU, Deinlein F, Mittler U, Urban C, Benesch M, Warmuth-Metz M, Soerensen N, Zwiener I, Goette H, Schlegel PG, Pietsch T, Kortmann RD, Kuehl J and Rutkowski S: Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. Eur J Cancer 45: 1209-1217, 2009.
2. Massimino M, Giangaspero F, Garrè ML, Gandola L, Poggi G, Biassoni V, Gatta G and Rutkowski S: Childhood medulloblastoma. Crit Rev Oncol Hematol 79: 65-83, 2011.
3. Gilbertson RJ: Medulloblastoma: signalling a change in treatment. Lancet Oncol 5: 209-218, 2004.
4. Leary SE and Olson JM: The molecular classification of medulloblastoma: driving the next generation clinical trials. Curr Opin Pediatr 24: 33-39, 2012.
5. Wierstra I and Alves J: FOXM1, a typical proliferation-associated transcription factor. Biol Chem 388: 1257-1274, 2007.
6. Laoukili J, Kooistra MR, Brás A, Kauw J, Kerkhoven RM, Morrison A, Clevers H and Medema RH: FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 7: 126-136, 2005.
7. Koo CY, Muir KW and Lam EW: FOXM1: from cancer initiation to progression and treatment. Biochim Biophys Acta 1819: 28-37, 2012.
8. Liu M, Dai B, Kang SH, Ban K, Huang FJ, Lang FF, Aldape KD, Xie TX, Pelloski CE, Xie K, Sawaya R and Huang S: FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res 66: 3593-3602, 2006.
9. Bektas N, Haaf At, Veeck J, Wild PJ, Lüscher-Firzlaff J, Hartmann A, Knüchel R and Dahl E: Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer 8: 42, 2008.
10. Ahmed M, Uddin S, Hussain AR, Alyan A, Jehan Z, Al-Dayel F, Al-Nuaim A, Al-Sobhi S, Amin T, Bavi P and Al-Kuraya KS: FoxM1 and its association with matrix metalloproteinase (MMP) signaling pathway in papillary thyroid carcinoma. J Clin Endocrinol Metab 97: E1-E13, 2012.
11. Xia JT, Wang H, Liang LJ, Peng BG, Wu ZF, Chen LZ, Xue L, Li Z and Li W: Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma. Pancreas 41: 629-635, 2012.
12. Priller M, Pöschl J, Abrão L, von Bueren AO, Cho YJ, Rutkowski S, Kretzschmar HA and Schüller U: Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. Clin Cancer Res 17: 6791-6801, 2011.
13. Carr JR, Park HJ, Wang Z, Kiefer MM and Raychaudhuri P: FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 70: 5054-5063, 2010.
14. Millour J, Constantinidou D, Stavropoulou AV, Wilson MS, Myatt SS, Kwok JM, Sivanandan K, Coombes RC, Medema RH, Hartman J, Lykkesfeldt AE and Lam EW: FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene 29: 2983-2995, 2010.
15. Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, Coombes RC, Myatt SS and Lam EW: FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res 8: 24-34, 2010.
16. Halasi M and Gartel AL: Suppression of FOXM1 sensitizes human cancer cells to cell death induced by DNA-damage. PLoS One 7: e31761, 2010.
17. Kwok JM, Myatt SS, Marson CM, Coombes RC, Constantinidou D and Lam EW: Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol Cancer Ther 7: 2022-2032, 2008.
18. Hegde NS, Sanders DA, Rodriguez R and Balasubramanian S: The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat Chem 3: 725-731, 2011.
19. Bhat UG, Halasi M and Gartel AL: FoxM1 is a general target for proteasome inhibitors. PLoS One 4: e6593, 2009.
20. Bhat UG, Halasi M and Gartel AL: Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS One 4: e5592, 2009.
21. Halasi M, Schraufnagel DP and Gartel AL: Wild-type p53 protects normal cells against apoptosis induced by thiostrepton. Cell Cycle 8: 2850-2851, 2009.
22. Halasi M, Zhao H, Dahari H, Bhat UG, Gonzalez EB, Lyubimo AV, Tonetti DA and Gartel AL: Thiazole antibiotics against breast cancer. Cell Cycle 9: 1214-1217, 2010.
23. Wang M and Gartel AL: Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts. Mol Cancer Ther 10: 2287-2297, 2011.
24. Wang Y, Wen L, Zhao SH, Ai ZH, Guo JZ and Liu WC: FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients. Lung Cancer 79: 173-179, 2013.
25. Zhang N, Wu X, Yang L, Xiao F, Zhang H, Zhou A, Huang Z and Huang S: FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clin Cancer Res 18: 5961-5971, 2012.
26. Xu N, Zhang X, Wang X, Ge HY, Wang XY, Garfield D, Yang P, Song YL and Bai CX: FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells. Acta Pharmacol Sin 33: 675-681, 2012.
27. Park HJ, Gusarova G, Wang Z, Carr JR, Li J, Kim KH, Qiu J, Park YD, Williamson PR, Hay N, Tyner AL, Lau LF, Costa RH and Raychaudhuri P: Deregulation of FoxM1b leads to tumour metastasis. EMBO Mol Med 3: 21-34, 2011.
28. Lok GT, Chan DW, Liu VW, Hui WW, Leung TH, Yao KM and Ngan HY: Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells. PLoS One 6: e23790, 2011.
29. Huang C, Qiu Z, Wang L, Peng Z, Jia Z, Logsdon CD, Le X, Wei D, Huang S and Xie K: A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer Res 72: 655-665, 2012.
30. Kim R, Emi M, Tanabe K and Toge T: Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 101: 2491-2502, 2004.